Literature DB >> 17374088

Vascular calcification and disordered mineral metabolism in dialysis patients.

Mary Alice Kalpakian1, Rajnish Mehrotra.   

Abstract

Vascular calcification is an active, cell-mediated process that can involve either the intima or media of the blood vessels. The current methods used to clinically measure vascular calcification cannot distinguish between intimal (invariably atherosclerotic) and medial calcification. The high calcification scores seen in patients with end-stage renal disease likely represent a composite of high calcification burden in both sites. The severity of vascular calcification has been associated with a variety of findings including left ventricular hypertrophy and angiographic vascular stenosis as well as with all-cause and cardiovascular mortality. There is increasing evidence that disordered mineral metabolism participates in the process of vascular calcification and is one of the mechanisms whereby hyperphosphatemia, hypercalcemia, and hyperparathyroidism enhance cardiovascular and all-cause mortality of end-stage renal disease patients. There are no studies showing improved outcomes of ESRD patients with aggressive control of disordered mineral metabolism. However, the preponderance of evidence argues strongly in favor of aggressive management of these abnormalities from starting early in the course of chronic kidney disease in the hope of improving patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17374088     DOI: 10.1111/j.1525-139X.2007.00261.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  20 in total

1.  Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients.

Authors:  Eric D Weinhandl; Jiannong Liu; David T Gilbertson; Thomas J Arneson; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

Review 2.  Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.

Authors:  Kamyar Kalantar-Zadeh; Anuja Shah; Uyen Duong; Rulin C Hechter; Ramanath Dukkipati; Csaba P Kovesdy
Journal:  Kidney Int Suppl       Date:  2010-08       Impact factor: 10.545

3.  Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS.

Authors:  Rachel B Fissell; Angelo Karaboyas; Brian A Bieber; Ananda Sen; Yun Li; Antonio A Lopes; Takashi Akiba; Jürgen Bommer; Jean Ethier; Michel Jadoul; Ronald L Pisoni; Bruce M Robinson; Francesca Tentori
Journal:  Hemodial Int       Date:  2015-05-14       Impact factor: 1.812

4.  Matrix vesicles induce calcification of recipient vascular smooth muscle cells through multiple signaling pathways.

Authors:  Neal X Chen; Kalisha D O'Neill; Sharon M Moe
Journal:  Kidney Int       Date:  2017-10-09       Impact factor: 10.612

5.  Comparative clinical outcomes between pediatric and young adult dialysis patients.

Authors:  Meredith A Atkinson; Rachel M Lestz; Barbara A Fivush; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2011-06-04       Impact factor: 3.714

6.  Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing.

Authors:  Anuja Shah; Clinton J Miller; Cynthia C Nast; Mark D Adams; Barbara Truitt; John A Tayek; Lili Tong; Parag Mehtani; Francisco Monteon; John R Sedor; Erica L Clinkenbeard; Kenneth White; Rajnish Mehrotra; Janine LaPage; Patricia Dickson; Sharon G Adler; Sudha K Iyengar
Journal:  Nephrol Dial Transplant       Date:  2014-11-05       Impact factor: 5.992

7.  No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.

Authors:  Rajnish Mehrotra; Carmen A Peralta; Shu-Cheng Chen; Suying Li; Michael Sachs; Anuja Shah; Keith Norris; Georges Saab; Adam Whaley-Connell; Bryan Kestenbaum; Peter A McCullough
Journal:  Kidney Int       Date:  2013-04-24       Impact factor: 10.612

8.  Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.

Authors:  Rajnish Mehrotra; Kevin J Martin; Steven Fishbane; Stuart M Sprague; Steven Zeig; Michael Anger
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-25       Impact factor: 8.237

9.  Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.

Authors:  Yi-Wen Chiu; Isaac Teitelbaum; Madhukar Misra; Essel Marie de Leon; Tochi Adzize; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 8.237

Review 10.  Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.

Authors:  Diego Brancaccio; Jürgen Bommer; Daniel Coyne
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.